Evastel

Quick links to important sections

Evastel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evastel

Quick Facts

Property Description
Active Ingredient Ebastine (INN)
Form Oral (Film-coated tablets, orodispersible tablets, syrup)
Pharmacological Class Second-Generation H₁-Receptor Antagonist
General Purpose Systemic Antiallergic Agent
Origin Synthetic Compound

What Type of Medicine is Evastel?

Evastel is a synthetic pharmaceutical preparation containing the active ingredient Ebastine, classified as a second-generation selective H₁-receptor antagonist, the official name for a type of non-sedating antihistamine. It is designed as a single-ingredient product taken via the oral route for systemic action throughout the body. The drug's status as a second-generation antihistamine is due to its molecular structure, which limits its ability to penetrate the central nervous system (CNS), a feature that fundamentally contributes to its non-sedating profile compared to older agents. This characteristic positions it favorably for typical use scenarios, such as managing seasonal discomfort while continuing daily professional or educational activities.


Composition and Available Drug Forms

The core active ingredient in Evastel is Ebastine, a compound of synthetic origin which the body metabolizes into its highly active, long-acting form, carebastine. The medication is available for oral administration in several formats, including standard film-coated tablets, specialized fast-dissolving orodispersible tablets (ODTs), and a pediatric syrup. This variety of dosage forms ensures flexible administration across different patient groups; for instance, the orodispersible tablet offers a distinctive feature, disintegrating rapidly in the mouth without requiring water for swallowing.


Fundamental Action and General Purpose

The general purpose of Evastel is to act as a systemic antiallergic agent that works to control the physical discomfort resulting from hypersensitivity reactions. The medication functions through the targeted blockade of peripheral histamine H₁ receptors, preventing histamine, a key chemical released by the immune system, from triggering symptoms. This selective mechanism helps mitigate the body’s exaggerated immune response, providing sustained control over general allergic symptoms.

What side effects are possible with Evastel?

Possible Side Effects and Safety Information

Regulatory documents classify the possible adverse effects of Evastel (Ebastine) based on the frequency of their occurrence in clinical studies and surveillance. These documented reactions are structurally organized by the physiological system they affect.


Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Common (affecting ge 1/100 to < 1/10 patients), include headache, somnolence (drowsiness), and dry mouth. Uncommon reactions, affecting the Nervous System and Gastrointestinal System, include nervousness, insomnia, nausea, abdominal pain, and dyspepsia (indigestion).

Reactions classified as Rare (affecting ge 1/10,000 to < 1/1,000 patients) involve other body systems. These include effects on the Cardiovascular System such as palpitations and tachycardia (rapid heart rate), as well as Hepatobiliary Disorders like hepatitis and changes indicated by abnormal liver function tests.


Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant adverse reactions, including severe hypersensitivity reactions such as anaphylaxis and angioedema.

Regulatory safety constraints specify that the medicine is contraindicated in patients with known hypersensitivity to the active substance. Furthermore, caution is required, and a dose limit is specified for individuals with severe hepatic impairment. Caution is also warranted for patients with known QTc interval prolongation or certain other cardiac risk factors.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Evastel (Ebastine) overdose focuses on the management of potential intensified effects and the necessity of immediate supportive care. Although studies involving doses up to 100 mg daily did not show any clinically significant signs, a large overdose carries the potential for increased risk of sedation and antimuscarinic effects.


Overdose Manifestations and Actions

Aspect Regulatory Statement
Manifestations May present with increased sedation and antimuscarinic effects. The development of central nervous symptoms is cited as a severe outcome that requires immediate attention and may necessitate intensive care.
Emergency Actions Seek immediate medical attention for symptomatic and supportive treatment. Intensive care may be required if central nervous symptoms develop.
Antidote Status No specific antidote for Ebastine is known or available.

Mandated Monitoring

Emergency medical care is required to ensure that essential management measures are promptly initiated, including gastric lavage and the administration of activated charcoal if considered appropriate. Continuous Electrocardiographic monitoring (ECG) is mandated as part of the management strategy, specifically involving evaluation of the QT interval for at least 24 hours. Monitoring of vital functions is also required. This comprehensive regulatory strategy is centered on supportive care, especially given the documented but minor increase in QTc interval seen at high doses.

Therapeutic Uses of Evastel

Evastel is an agent indicated for the symptomatic management of certain allergic conditions. The therapeutic domain includes allergic rhinitis, which may be seasonal or perennial in nature. This use addresses the symptoms associated with the condition, such as sneezing, runny nose, and nasal discomfort.

Evastel is also utilized in the management strategy for chronic idiopathic urticaria. In this context, it contributes to the relief of hives and associated itching (pruritus). The medication is approved for these specified uses in multiple global markets.


Quick Facts

  • Relief target: Allergic rhinitis symptoms (seasonal and perennial)
  • Other use: Management of chronic idiopathic urticaria
  • Primary function: Contributes to the reduction of symptoms like sneezing, nasal discharge, and pruritus

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Evastel (Ebastine) use is defined by official regulatory documentation based on age, physiological status, and pre-existing health conditions.

Populations Approved for Use

The medicine is approved for use in adults and adolescents (mathbfge 12 years). For pediatric patients, the tablet formulation is approved for children mathbfge 6 years, and the oral solution/syrup is approved for children mathbfge 2 years. Use is permitted in older adults and patients with renal impairment or mild to moderate hepatic impairment with no need for a dose adjustment.

Absolute Contraindications

Evastel is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance or its excipients. Use is also officially contraindicated in women who are breastfeeding (lactation). Furthermore, some global regulatory labels state that the medicine must not be used in patients with severe hepatic insufficiency.

Conditions Requiring Caution

Use is not recommended during pregnancy as a precautionary measure, due to limited data. For patients with severe hepatic impairment, caution is advised, and the maximum daily dose is restricted. Caution is also required for individuals with known QTc interval prolongation and those with certain excipient-related metabolic disorders.

What should I know about interactions with other medicines?

Evastel Interactions with other medicines and products

The official regulatory interaction profile for Evastel (Ebastine) is defined by documented pharmacokinetic alterations involving drug metabolism and co-administration with food.


Documented Pharmacokinetic Interactions

Co-administration with certain medicinal products results in pharmacokinetic interactions that formally alter the plasma concentration of ebastine and its active metabolite, carebastine.

  • Increased Exposure (CYP3A4 Inhibition): Combining Evastel with CYP450 3A4 enzyme inhibitors, such as the antifungals ketoconazole and itraconazole or the antibiotic erythromycin, leads to higher plasma concentrations of ebastine. This is classified in regulatory documents as a CYP enzyme-mediated interaction.
  • Decreased Exposure (CYP Induction): Co-use with the CYP inducer rifampicin is documented to cause a reduction in the plasma concentrations of ebastine.
  • Pharmacodynamic Precaution: Caution is officially advised when co-administering Evastel with medicinal products known to prolong the QTc interval.

Interactions with Food and Specific Substances

The regulatory label explicitly notes that administration of Evastel with food increases the plasma levels of carebastine by 1.5- to 2.0-fold. Regarding other substances, formal studies documented no reported interaction between Evastel and alcohol or diazepam. Similarly, no interaction effects were found with theophylline, warfarin, or cimetidine.

Population-Specific Note: Caution is officially advised for patients with severe hepatic impairment, as their condition relates to the drug's metabolic profile, potentially impacting interaction severity.

Mechanism of Action

Selective Pharmacodynamic Mechanism

Evastel's action is defined by the mechanism of its primary active metabolite, Carebastine, which functions as a highly selective antagonist of peripheral Histamine H1 Receptors. Carebastine binds to these receptors with high affinity, physically occupying the site and preventing the endogenous mediator Histamine from accessing and initiating its signaling cascade. This mechanism ensures that the drug's activity is predominantly peripheral, due to the active metabolite’s limited capacity to cross the Blood-Brain Barrier.

Pathway Modulation and Physiological Consequences

This functional antagonism modulates two critical physiological processes downstream of H1 receptor activation. By suppressing Histamine's effect on microvascular endothelium, the blockade limits Histamine-induced disruption of the endothelial barrier and subsequent changes in vascular permeability. Simultaneously, the mechanism reduces the Histamine-induced excitation of peripheral sensory neurons. The sustained nature of this effect is established by the slow dissociation kinetics of Carebastine from the H1 Receptor, maintaining functional receptor blockade over an extended period.

Dosage and Administration Information

How to Use Evastel

Evastel (ebastine) is intended exclusively for oral administration, with the dosing schedule standardized to be taken once daily. The medication is available as film-coated tablets, orodispersible tablets (ODTs), and syrup.


Standard Adult Dosing and Frequency

Indication Standard Dose Maximum Dose Frequency
Allergic Rhinitis / Urticaria (Adults ge 12 yrs) 10 mg 20 mg (for severe symptoms) Once Daily

The typical starting dose for adults and children aged 12 years and over is 10 mg once daily. For severe symptoms of allergic rhinitis, the dose may be increased to 20 mg once daily. Treatment duration is determined by clinical need and may be prolonged until symptoms are resolved.


Administration Conditions and Adjustments

Evastel offers flexibility in administration, as it may be taken independently of meals (with or without food). Specific instructions exist for different forms: film-coated tablets should be swallowed whole with liquid, while the orodispersible tablets are designed to disintegrate on the tongue without requiring water for swallowing.

No dose adjustment is typically required for older adults or in cases of renal impairment. However, a specific constraint is applied for patients with severe hepatic impairment, where the daily dose must not exceed 10 mg. If a dose is missed, it is advised not to take a double dose to compensate.

Recent Clinical Evidence

Evastel: Recent Clinical Evidence


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring how symptoms change over time in conditions like allergic rhinitis is primarily based on Randomized Controlled Trials (RCTs). These studies involve adult and adolescent populations and examine fluctuating symptoms such as hay fever. Researchers monitored patient-reported outcomes, specifically measuring changes in the Total Nasal Symptom Scores (TNSS) (sneezing, nasal discharge, itching). Most studies explored short-term changes over intervals of a few weeks to three months. The research base consists of numerous RCTs summarized in scientific reviews. However, long-term outcomes when using the medication continuously over many months are not fully characterized, and follow-up durations were limited in most trials.

Evidence for Use in Chronic Idiopathic Urticaria

Evastel was also evaluated in studies examining Chronic Idiopathic Urticaria (CIU), a condition involving persistent hives and itching. Research relies on placebo-controlled RCTs in adult populations. Studies measured disease activity using endpoints like the severity of itching (pruritus) and the number of wheals, tracked by the Urticaria Symptom Severity Scores (UAS). Research describes patterns of changes measured in these scores during study periods, typically around 28 days. Evidence is limited regarding the use of doses exceeding the standard licensed dose, and long-term effects are not fully established regarding disease stability.

Long-Term Studies and Duration of Follow-up

Most evidence is from short-term to intermediate-term follow-up periods. This means the research provides context for acute changes in physical discomfort, but there is limited information for long-term outcomes regarding the sustained consistency of symptom patterns over periods exceeding three months.

Evidence in Specific Populations and Uncertainties

Studies have evaluated adolescents and younger children (2 to 11 years) with allergies. For younger children, evidence is available but primarily relies on smaller-scale trials, sometimes focused on liquid forms, meaning data for these groups remain insufficient. The primary evidence gap is the lack of long-term data and limited research on physiological outcomes, such as temporary functional imbalance and changes in inflammatory markers. Comparative evidence with some other second-generation antihistamines also remains limited.

Frequently Asked Questions (FAQ)

Common questions about Evastel (FAQ)


Q: Is Evastel considered a long-term medication?

According to official product information, the duration of treatment is determined by a healthcare provider based on the individual's symptoms and clinical need. Regulatory labels indicate that treatment may be prolonged until symptoms are resolved, suggesting it can be used for extended periods as necessary.

Q: How long does it typically take to start feeling the effects of Evastel?

Evastel is an inactive compound that must first be metabolized by the liver into its active form, carebastine. Regulatory sources and studies describe the time to maximum plasma concentration of the active metabolite as generally occurring between one and three hours after administration. This characteristic indicates that the medicine is not suitable for the immediate relief of severe, acute allergic reactions.

Q: How does Evastel affect the liver or kidneys?

Official documentation states that caution is advised for patients with severe hepatic impairment (severe liver disease), and a specific dosage restriction is applied to this group. Conversely, regulatory documents indicate that a dose adjustment is typically not required for patients with renal impairment (kidney issues).

Q: Do I need to get blood tests done while I am taking Evastel?

Regulatory guidance advises screening for certain risk factors, particularly for patients with a history of heart issues, which may involve blood tests to check potassium levels or a baseline ECG (a heart tracing). Decisions regarding routine monitoring while on the medicine are made by a qualified healthcare professional.

Q: What are the signs of a serious, but rare, side effect from Evastel?

Rare but clinically significant adverse reactions that have been documented include severe hypersensitivity reactions (allergic reactions). These may present as anaphylaxis or angioedema, which is a severe swelling of the face, lips, tongue, or throat. Official guidance indicates that these effects are clinically significant and require professional medical evaluation.

Q: Does Evastel have an impact on fertility or pregnancy planning?

The use of Evastel is not recommended during pregnancy as a precautionary measure, due to limited data regarding its safety for the unborn child. Official regulatory documents do not provide specific information on effects concerning fertility or pre-conception planning.

Q: What does the term 'contraindication' mean in relation to Evastel?

A contraindication is a medical condition or factor that means a specific treatment should not be given because it could pose a risk to the patient. For Evastel, an example of an absolute contraindication is a known hypersensitivity (severe allergic reaction) to the active substance or any of its inactive ingredients.

Q: Is it safe to drive or operate machinery while on Evastel?

Evastel is classified as a non-sedating antihistamine, and many patients can drive or carry out activities requiring full attention. However, because somnolence (drowsiness) or dizziness may occur in some individuals, official product information notes that individuals should be aware of their personal response to the medication before engaging in activities that require concentration.

Q: Does the time of day I take Evastel matter?

The medication is standardized to be taken once daily. Regulatory documents do not specify a preferred time of day (morning versus evening). It may be taken independently of meals, meaning the dose can be administered with or without food.

Q: Can Evastel be crushed or split if a person has trouble swallowing?

Official instructions state that the film-coated tablets should be swallowed whole with liquid. For patients who may have difficulty swallowing tablets, Evastel is also available as orodispersible tablets (ODTs) which are specifically designed to disintegrate on the tongue without needing water.

Q: What kind of monitoring is typically required while on Evastel?

Caution is advised for patients with existing heart problems or related risk factors. For these individuals, regulatory documents indicate that monitoring of the QTc interval (heart rhythm) and electrolyte levels may be required before and periodically during therapy, especially when used concurrently with other interacting medicines.

Q: Why is Evastel not recommended for people with certain heart conditions?

Caution is advised for people with a known prolongation of the QTc interval on the ECG (heart tracing). The QTc interval is a measure of the electrical recovery time of the heart, and its excessive prolongation can potentially lead to a serious irregular heart rhythm.

Q: What does it mean if Evastel is 'metabolized by the liver'?

Evastel is an inactive compound that must be chemically changed, or metabolized, by the liver into its active form, carebastine. This conversion process is essential for the drug to work, which is why official safety constraints and dosage limits apply to people with severe liver impairment.

Q: Does Evastel contain any common allergens like gluten or lactose?

Official information regarding the excipients (inactive ingredients) states that some formulations, such as the orodispersible tablets (ODTs), contain lactose. The medicine is contraindicated for use in patients who have rare hereditary problems of galactose intolerance or lactose deficiency.

How should Evastel be stored and disposed of?

How to Store and Dispose of Evastel (Ebastine)

Evastel must be stored and handled according to the instructions on its regulatory label to maintain quality and prevent accidental access.


Official Storage Conditions

The medicine should be stored below 30^circC or below 25^circC depending on the formulation. It is mandatory to store Evastel in the original package to ensure it is protected from light, heat, and moisture. Consistent with all medical products, it must be stored out of the sight and reach of children.


Disposal Instructions

There are no special requirements for the disposal of Evastel. Any unused or expired medicine must be discarded in accordance with local/regional/national regulations. It is important to avoid letting the product enter drains or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Evastel found in:

A-Z Index: